2X Blend Tesamorelin (10mg) / Ipamorelin (5mg)

This blend combines two complementary growth hormone–releasing peptides—Tesamorelin and Ipamorelin—intended for preclinical research exploring GH-axis modulation with dual receptor activation mechanisms. 

• Tesamorelin is a synthetic 44–amino-acid GHRH analogue, N-terminally modified with trans‑3‑hexenoic acid. It targets GHRH receptors in the pituitary, promoting endogenous, pulsatile GH secretion and used in research on metabolism, body composition, and endocrine signaling [1]. 
• Ipamorelin is a selective ghrelin receptor (GHS‑R1a) agonist, a pentapeptide that induces GH release without affecting cortisol or prolactin levels, supporting investigation into GH pulsation, metabolism, and anabolic processes [2][3]. 

When used together, Tesamorelin initiates GH-axis activation via GHRH receptor pathways, while Ipamorelin amplifies GH release through ghrelin receptor stimulation. This dual-mechanism approach enables robust GH secretion in research frameworks, supporting studies into metabolic regulation, tissue repair, and neuroendocrine function. 

Citations

1. PubChem Compound Summary for Tesamorelin (CID 16137828): 44‑amino‑acid GHRH analogue with trans‑3‑hexenoic acid; MW ~5,196 Da.   
2. PubChem Compound Summary for Ipamorelin (CID 9831659): pentapeptide Aib–His–D‑2‑Nal–D‑Phe–Lys–NH₂; MW 711.9 Da. 
3. Peptides.org summary: “Ipamorelin is a selective GHSR agonist that induces GH-release without raising cortisol or prolactin.” 
4. BiotechPeptides research article: “Tesamorelin & Ipamorelin: Studying their Potential in GH Production” explores complementary mechanisms and metabolic applications.